On September 16, 2016, we purchased the assets of Compass Medical, Inc. ("Compass'') for approximately $16,000. The purchase price was financed with bank credit facility borrowings. Compass specializes in the sale and repair of flexible endoscopes. Prior to the acquisition, Compass generated annual revenues of approximately $6,000 and was integrated into our Healthcare Specialty Services segment.

On August 31, 2016, we purchased 100% of the shares of Phoenix Surgical Holdings, Ltd. and the assets of Endo-Tek LLP ("Phoenix Surgical and Endo-Tek") for approximately $14,300 combined, net of cash acquired. The purchase price was financed with cash on hand. Prior to the acquisition, these operations, which specialize in the repair of endoscopes, generated approximately $8,000 in combined annual revenue and were integrated into our Healthcare Specialty Services segment.

On July 22, 2016, we purchased 100% of the shares of Medisafe Holdings, Ltd. ("Medisafe"), a U.K. manufacturer of washer/disinfector equipment and related consumables and services for approximately $34,500, net of cash acquired. The purchase price was financed with cash on hand. Prior to the acquisition, the Medisafe product line generated $18,000 in annual revenue. The acquisition of Medisafe provides washer manufacturing and research and development capabilities in the U.K. Medisafe's products and services are being integrated into our Healthcare Products segment.

The table below summarizes the allocation of the purchase price to the net assets acquired based on fair values at the acquisition dates for our fiscal 2019, 2018 and 2017 acquisitions.



	Fiscal Year 2019			Fiscal Year 2018			Fiscal Year 2017
(dollars in thousands)	All Acquisitions (1)			All Acquisitions			Medisafe			Compass			Phoenix Surgical and Endo-Tek
Cash	$	—		$	235		$	3,751		$	—		$	769
Accounts receivable	750			1,464			3,634			629			1,123
Inventory	51			2,289			2,454			659			950
Property, plant and equipment	2,004			3,381			639			13			1,092
Other assets	479			126			—			31			46
Intangible assets	4,070			17,404			17,151			5,992			7,824
Goodwill	6,614			32,384			19,599			8,987			5,938
Total Assets	13,968			57,283			47,228			16,311			17,742
Current liabilities	(146		)	(2,077		)	(5,562		)	(309		)	(1,373		)
Non-current liabilities	(509		)	(2,679		)	(3,398		)	—			(1,263		)
Total Liabilities	(655		)	(4,756		)	(8,960		)	(309		)	(2,636		)
Net Assets	$	13,313		$	52,527		$	38,268		$	16,002		$	15,106

Acquisition related transaction and integration costs totaled $8,901, $16,211, and $30,082 for the fiscal years ended March 31, 2019, 2018, and 2017, respectively. These costs are included in Selling, general, and administrative expenses in the Consolidated Statements of Income.

On November 20, 2017, we sold our Synergy Health Healthcare Consumable Solutions ("HCS") business to Vernacare. Annual revenues for the HCS business were approximately $40,000 and were included in the Healthcare Products segment. We recorded proceeds of $8,891, net of cash divested, including a working capital adjustment. We also recognized a pre-tax loss on the sale, subject to final working capital adjustments, of $13,021 in Selling, general, and administrative expense in the Consolidated Statement of Income.

On February 9, 2017, we sold our Synergy Health Netherlands Linen Management Services business to EMEA B.V. Annual revenues for Synergy Health Netherlands Linen Management Services were approximately $75,000 and were included in the Healthcare Specialty Services segment. We recorded a $43,000 pre-tax loss on the sale in Selling, general, and administrative expense in the Consolidated Statements of Income as a result of the divestiture.

On November 3, 2016, we sold our Synergy Health U.S. Linen Management Services business to SRI Healthcare LLC. Annual revenues for U.S. Linen Management Services were approximately $50,000 and were included in the Healthcare Specialty Services segment. We recorded proceeds of $4,500 and recognized a pre-tax loss on the sale, subject to final adjustments, of $31,200 in Selling, general, and administrative expense in the Consolidated Statements of Income.

On September 2, 2016, we sold Synergy Health Laboratory Services to SYNLAB International. Annual revenues for the Synergy Health Labs were approximately $15,000 and were included in the Applied Sterilization Technologies segment. We recorded proceeds of $26,300, net of cash divested, and recognized a pre-tax gain on the sale of $18,700 in Selling, general, and administrative expense in the Consolidated Statements of Income.

On August 31, 2016, we completed the sale of our Applied Infection Control ("AIC") product line to DEB USA, Inc., a wholly-owned subsidiary of S.C. Johnson & Son, Inc. Annual revenues for the AIC product line were typically less than $50,000 and were included in the Healthcare Products segment. We recorded proceeds of $41,800 and recognized a pre-tax gain on the sale of $36,200 in Selling, general, and administrative expense in the Consolidated Statements of Income.

On July 1, 2016, we sold our Synergy Health UK Linen Management Services business to STAR Mayan Limited. Annual revenues for UK Linen Management Services were approximately $50,000 and were included in the Healthcare Specialty Services segment. We recorded proceeds of $65,400, net of cash divested, and recognized a pre-tax loss on the sale of $66,400 in Selling, general, and administrative expense in the Consolidated Statements of Income.

In connection with a fiscal 2019 equity investment of $4,955, we agreed to provide a credit facility of up to approximately $10,000 for a term of up to 7 years. Loans carry an interest rate of 4% compounded daily and interest is payable annually. Outstanding borrowings under the agreement totaled $7,465 at March 31, 2019.

In connection with the fiscal 2017 divestiture of Synergy Health Netherlands Linen Management Services, we entered into a loan agreement to provide financing of up to €15,000 for a term of up to 15 years. The loan carries an interest rate of 4% for the first four years and 12% thereafter. Outstanding borrowings under the agreement totaled $8,494 (or €7,550) at March 31, 2019.